EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nectin4 as a Promising Target for CAR-NK Cell Therapy in Breast Cancer Treatment

Jianchun Lian, Xinyu Li, Tianlong Xu, Tingwei Zhu, Xin Huang, Cheng Wei, Ai Zhao, Jimin Gao

Frontiers in Bioscience-Landmark · 2026

DOI: 10.31083/fbl54654 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2026. Verfasst von Jianchun Lian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, 325035 Wen…. Hauptthemen laut MEDLINE: Cell Adhesion Molecules, Killer Cells, Natural, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Construction Fund of Wenzhou Municipal Science and Technology Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer continues to be a major global health burden, with a significant proportion of patients developing metastatic or treatment-resistant disease. Novel therapeutic strategies are urgently needed. Nectin cell adhesion molecule 4 (Nectin4), an adhesion molecule overexpressed in aggressive breast cancer subtypes, represents a promising target for immunotherapy due to its restricted expression in normal tissues. This study investigated the therapeutic potential of Nectin4-directed chimeric antigen receptor natural killer (CAR-NK) cell therapy against triple-negative breast cancer (TNBC) at the preclinical stage.

Methods

Human natural killer (NK) cells obtained from peripheral blood from healthy donors were engineered to express an anti-Nectin4 chimeric antigen receptor (CAR) via lentiviral transduction, expanded ex vivo, and then used for functional studies. Cytotoxic activity was assessed in vitro against Nectin4-high-expressing breast cancer cells using luciferase-based killing assays at various effector-to-target ratios. In vivo efficacy was evaluated in NOD/SCID/IL2rγnull (NSG) mice bearing subcutaneous breast cancer tumors treated with CAR-NK cells, compared to untransduced NK cells and phosphate-buffered saline controls. Tumor growth was monitored using bioluminescence imaging and harvested tumors were subsequently analyzed for Nectin4 expression using immunohistochemistry.

Results

CAR-NK cells potently and specifically lysed Nectin4-positive breast cancer cells in vitro, with up to 95% target cell lysis at an effector-to-target ratio of 5:1. In vivo, CAR-NK treatment reduced tumor burden and prolonged survival compared with controls. Immunohistochemical analysis revealed a marked reduction in Nectin4 expression within tumors from the CAR-NK-treated group, consistent with targeted tumor cell elimination.

Conclusions

CAR-NK cells targeting Nectin4 demonstrated potent cytotoxic activity in vitro and effectively suppressed tumor growth in vivo, supporting the further evaluation of Nectin4 as a therapeutic target for CAR-NK-based immunotherapy in TNBC, particularly for aggressive subtypes with limited treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell Adhesion MoleculesKiller Cells, NaturalReceptors, Chimeric AntigenImmunotherapy, AdoptiveTriple Negative Breast NeoplasmsBreast NeoplasmsHumansAnimalsFemaleMiceMice, SCIDCell Line, TumorMice, Inbred NODXenograft Model Antitumor AssaysNectins

Stichwörter der Autor:innen

CAR-NK cell therapyNectin4breast cancerimmunotherapytargeted therapy

Substanzen

Cell Adhesion MoleculesNECTIN4 protein, humanReceptors, Chimeric AntigenNectins

Autor:innen und Institutionen

  • Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, 325035 Wenzhou, Zhejiang, China.
  • Department of Medical Laboratory, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, 223300 Huaian, Jiangsu, China.
  • Department of Geriatric, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, 310022 Hangzhou, Zhejiang, China.

Förderung

  • Construction Fund of Wenzhou Municipal Science and Technology Research Program

Zitieren

APA

Lian, J., Li, X., Xu, T., Zhu, T., Huang, X., Wei, C., Zhao, A., & Gao, J. (2026). Nectin4 as a Promising Target for CAR-NK Cell Therapy in Breast Cancer Treatment. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl54654

Vancouver

Lian J, Li X, Xu T, Zhu T, Huang X, Wei C, et al. Nectin4 as a Promising Target for CAR-NK Cell Therapy in Breast Cancer Treatment. Frontiers in Bioscience-Landmark. 2026. doi:10.31083/fbl54654

BibTeX
@article{Lian2026,
  author = {Lian, Jianchun and Li, Xinyu and Xu, Tianlong and Zhu, Tingwei and Huang, Xin and Wei, Cheng and Zhao, Ai and Gao, Jimin},
  title = {Nectin4 as a Promising Target for CAR-NK Cell Therapy in Breast Cancer Treatment},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2026},
  doi = {10.31083/fbl54654}
}
Kostenlos starten →